Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Regenxbio Inc(RGNX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RGNX
10/15/2026: RGNX (1-star) is currently NOT-A-BUY. Pass it for now.
Regenxbio is a clinical-stage biotechnology company that utilizes its proprietary NAV AAV vector technology to develop gene therapies. The company maintains a dual-revenue approach by licensing its platform to partners and developing its own internal therapeutic candidates, notably RGX-314 for retinal diseases. While the partnership with AbbVie provides a strong foundation and validation of its platform, the company faces significant execution and regulatory risks inherent to the biotechnology sector. It is best suited for investors with a high risk tolerance who are interested in the long-term potential of genetic medicine, keeping a close eye on clinical data readouts and regulatory milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-growth potential linked to gene therapy innovation, but is subject to binary clinical trial outcomes. |
| Momentum investor | Weak fit | Momentum fits only if specific positive clinical data or partnership catalysts trigger a sustained uptrend. |
| Value investor | Weak fit | The company is not currently profitable, making traditional value metrics difficult to apply. |
| Dividend investor | Weak fit | No dividends are paid, and none are expected in the near term. |
| Low-risk investor | Weak fit | High clinical and regulatory risks make this stock unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are highly sensitive to clinical trial news and regulatory updates. |
| Valuation risk | Medium / high | Valuations are speculative and depend heavily on future commercial success. |
| Competition risk (gene therapy) | High | Many well-funded rivals are developing competing gene therapy approaches. |
| Business quality | Medium | While the technology is sound, the business is still proving its commercial viability. |
| Dividend income | Low / none | Capital is strictly allocated to R&D, precluding dividends. |
| Execution risk | High | Successful drug development and manufacturing scale-up are complex and uncertain. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -75.35% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 454.17M USD | Price to earnings Ratio - | 1Y Target Price 23.58 |
Price to earnings Ratio - | 1Y Target Price 23.58 | ||
Volume (30-day avg) 1.4M shares | Beta 1.13 | 52 Weeks Range 5.46 - 16.19 | Updated Date 10/15/2026 |
52 Weeks Range 5.46 - 16.19 | Updated Date 10/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.58 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| NAV Technology Licensing | Upfront payments, milestone payments, and royalties from partners using NAV vectors. | Revenue is earned by renting out their core gene-delivery tech to other drug makers. |
| Therapeutic Development | Future potential revenue from the commercial sale of self-developed gene therapies. | The company is investing heavily to build its own future line of medicine products. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 458.20M | Price to Sales(TTM) 2.6 |
Enterprise Value 458.20M | Price to Sales(TTM) 2.6 | ||
Enterprise Value to Revenue 2.63 | Enterprise Value to EBITDA -3.37 | Shares Outstanding 66.01M | Shares Floating 57.23M |
Shares Outstanding 66.01M | Shares Floating 57.23M | ||
Percent Insiders 6.55 | Percent Institutions 65.26 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.